Announced
Completed
Financials
Tags
diabetes medicines
Pharmaceuticals
Domestic
Friendly
United States
Acquisition
Majority
Private
Completed
Single Bidder
Synopsis
Amphastar Pharmaceuticals, a specialty pharmaceutical company, completed the acquisition of BAQSIMI, a diabetes medication from Eli Lilly, a pharmaceutical company, for $1.1bn. "We are pleased to execute our strategy to accelerate the expansion of our branded products and diabetes portfolio, as evidenced by the successful completion of the acquisition of BAQSIMI. We have further strengthened our commercial product portfolio by adding BAQSIMI while remaining committed to our core business. We are committed to maximizing the commercial potential of BAQSIMI while assisting people with diabetes worldwide," Jack Zhang, Amphastar President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.